Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07297979 · ClinicalTrials.gov registry record · Phase 1

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

A Phase 1 study of Ewing Sarcoma, sponsored by Amgen.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
2
Study locations

NCT07297979 is a Phase 1 study of Ewing Sarcoma that is actively recruiting participants, run by Amgen. The registered enrollment target is 50 participants, below the 108-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07297979, a Phase 1 study of Ewing Sarcoma, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

Conditions Studied

Ewing Sarcoma

Interventions

  • DRUG Xaluritamig

Study Locations (2)

California

  • University of California Los Angeles - Los Angeles

Victoria

  • Peter MacCallum Cancer Centre - Melbourne

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-04-01
Est. Completion 2030-05-26
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07297979

The ClinicalTrials.gov registry entry for NCT07297979 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (54% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ewing Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Xaluritamig is the first listed.

NCT07297979 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Victoria.

Frequently Asked Questions

What is clinical trial NCT07297979 about?

NCT07297979 is a clinical study titled "Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)". The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

What is the current status of trial NCT07297979?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-04-01. Estimated completion is 2030-05-26.

What conditions does trial NCT07297979 study?

This clinical trial studies the following conditions: Ewing Sarcoma.

What interventions are being tested in trial NCT07297979?

The interventions under investigation include: Xaluritamig (DRUG).

Who is sponsoring clinical trial NCT07297979?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07297979 being conducted?

This trial has 2 study locations across California, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ewing Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ewing Sarcoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.